Imugene Ltd

Research Imugene Ltd (IMU) on Bullrun: market cap AUD 48.84M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMU
• ExchangeAU
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyAUD
• Market capAUD 48.84M
• Financial periodFY2025
• Net income-AUD 69.02M
• Free cash flow-AUD 90.03M

Valuation Snapshot

latest market cap is AUD 48.84M.

About Imugene Ltd

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia;

Frequently asked questions

What is Imugene Ltd's market cap?

Imugene Ltd's market capitalization is AUD 48.84M.

What does Imugene Ltd do?

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.